Phenylpropanolamine: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Nasal congestion

Adult: Per cap contains a combination w/ phenylpropanolamine HCl 18 mg: ≥13 yr 2 cap 4 hrly. Max: 8 cap/day. Per tab contains a combination w/ phenylpropanolamine HCl 25 mg: ≥13 yr 1 tab 4 hrly. Max: 4 tab/day.
Child: Per cap contains a combination w/ phenylpropanolamine HCl 18 mg: 6-12 yr 1 cap 4 hrly. Max: 4 cap/day. As oral liquid containing phenylpropanolamine 2.5 mg/5 mL: 6 mth-2 yr 2.5 mL tid, 3-5 yr 5 mL 3-4 times daily, 6-12 yr 5-10 mL 3-4 times daily.

Contraindications

Concurrent use or w/in 14 days after stopping MAOI.

Special Precautions

Hyperthyroidism, DM, ischaemic heart disease, HTN, renal impairment, closed-angle glaucoma. Patients who are overweight, or w/ eating disorders. May precipitate anginal pain in patients w/ angina pectoris. Elderly, pregnancy and lactation.

Adverse Reactions

HTN, headache, confusions, anxiety, dizziness, restlessness, insomnia, agitations, palpitations, tremors, blurred vision.
Potentially Fatal: Hypertensive crisis, haemorrhagic stroke.

Pregnancy Category (US FDA)

PO: C

Patient Counseling Information

May impair ability to drive or operate machinery.

Overdosage

Symptoms: Rapid pulse and respiration, disorientation, elevated BP, tachycardia, mydriasis, headache, CNS excitation, nausea, vomiting and anorexia. Management: Symptomatic and supportive treatment. Induced emesis and gastric lavage immediately.

Drug Interactions

Increased risk of HTN w/ indometacin. Increased risk of psychosis w/ amantadine.
Potentially Fatal: Increased risk of potentially fatal hypertensive crisis w/ or w/in 14 days after stopping MAOI. Increased risk of severe HTN and complications w/ bromocriptine.

Food Interaction

Further increased BP w/ caffeine.

Action

Description: Phenylpropanolamine is an indirect acting sympathomimetic, often used orally as the HCl salt for nasal congestion. It has been withdrawn in several countries due to increased risk of haemorrhagic strokes.
Pharmacokinetics:
Absorption: Readily and completely absorbed from GI tract. Time to peak plasma concentration: 1-2 hr.
Metabolism: Undergoes partial hepatic metabolism.
Excretion: Via urine 80-90% (unchanged). Half-life: Approx 3-5 hr.

Storage

Store below 25°C.

MIMS Class

Cough & Cold Preparations

Disclaimer: This information is independently developed by MIMS based on Phenylpropanolamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com